ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NRSN NeuroSense Therapeutics Ltd

2.1364
0.0864 (4.21%)
Last Updated: 09:07:24
Delayed by 15 minutes

Period:

Draw Mode:

Volume 192,338
Bid Price 2.09
Ask Price 2.14
News -
Day High 2.29

Low
0.40

52 Week Range

High
2.33

Day Low 1.98
Share Name Share Symbol Market Stock Type
NeuroSense Therapeutics Ltd NRSN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.0864 4.21% 2.1364 09:07:24
Open Price Low Price High Price Close Price Previous Close
2.21 1.98 2.29 2.05
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
517 192,338 US$ 2.18 US$ 418,533 - 0.40 - 2.33
Last Trade Type Quantity Price Currency
09:07:24 2,000 US$ 2.1364 USD

NeuroSense Therapeutics Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
25.23M 11.79M - 0 -12.34M -1.05 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

NeuroSense Therapeutics News

Date Time Source News Article
2/22/202407:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/21/202407:30PR Newswire (US)NeuroSense Reports Additional Positive Results from its ALS..
2/13/202412:20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/13/202409:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/07/202408:38Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/07/202408:27PR Newswire (US)NeuroSense Regains Compliance with NASDAQ Minimum Bid Price..
1/09/202407:49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/09/202407:48Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/09/202407:45PR Newswire (US)NeuroSense Recaps Positive 2023 Achievements Including..
12/27/202316:03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
12/27/202316:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/27/202316:00PR Newswire (US)NeuroSense Announces Receipt of Nasdaq Notice Regarding..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No NRSN Message Board. Create One! See More Posts on NRSN Message Board See More Message Board Posts

Historical NRSN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.252.331.251.831,099,1840.886470.91%
1 Month1.282.331.101.59505,7060.856466.91%
3 Months0.7422.330.61161.23367,1031.39187.92%
6 Months0.872.330.401.03561,8431.27145.56%
1 Year1.792.330.401.08307,1090.346419.35%
3 Years4.558.180.403.571,236,087-2.41-53.05%
5 Years4.558.180.403.571,236,087-2.41-53.05%

NeuroSense Therapeutics Description

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com